News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Research Corporation Technologies Demonstrates Long Half-Life of the CH2 Domain, a New Antibody-Derived Scaffold


7/11/2012 9:57:22 AM

TUCSON, Ariz.--(BUSINESS WIRE)--Research Corporation Technologies (RCT) and the Protein Interactions Group of the National Cancer Institute at the National Institutes of Health (NIH) have published the first studies in primates that characterize the long half-life of isolated CH2 domains, a new antibody-derived scaffold. The work was performed under a Cooperative Research and Development Agreement (CRADA) between RCT and the NIH.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES